Accessibility Menu
 
Tandem Diabetes Care logo

Tandem Diabetes Care

(NASDAQ) TNDM

Current Price$19.62
Market Cap$1.43B
Since IPO (2013)-89%
5 Year-78%
1 Year+2%
1 Month-23%

Tandem Diabetes Care Financials at a Glance

Market Cap

$1.43B

Revenue (TTM)

$1.01B

Net Income (TTM)

$204.71M

EPS (TTM)

$-3.07

P/E Ratio

-6.84

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$19.62

Volume

110,304

Open

$21.20

Previous Close

$19.62

Daily Range

$19.54 - $21.20

52-Week Range

$9.98 - $29.65

TNDM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tandem Diabetes Care

Industry

Healthcare Equipment and Supplies

Employees

2,500

CEO

John F. Sheridan, MBA

Headquarters

San Diego, CA 92121, US

TNDM Financials

Key Financial Metrics (TTM)

Gross Margin

54%

Operating Margin

-18%

Net Income Margin

-20%

Return on Equity

-98%

Return on Capital

-29%

Return on Assets

-23%

Earnings Yield

-14.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.43B

Shares Outstanding

68.33M

Volume

110.30K

Short Interest

0.00%

Avg. Volume

1.96M

Financials (TTM)

Gross Profit

$530.85M

Operating Income

$78.12M

EBITDA

$174.70M

Operating Cash Flow

$9.72M

Capital Expenditure

$19.95M

Free Cash Flow

$29.67M

Cash & ST Invst.

$292.67M

Total Debt

$444.48M

Tandem Diabetes Care Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$290.38M

+2.7%

Gross Profit

$167.46M

+6.4%

Gross Margin

57.67%

N/A

Market Cap

$1.43B

N/A

Market Cap/Employee

$541.45K

N/A

Employees

2,650

N/A

Net Income

$589.00K

-178.0%

EBITDA

$11.25M

+83.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$271.68M

-671.0%

Accounts Receivable

$165.49M

+44.4%

Inventory

$128.77M

-13.9%

Long Term Debt

$539.97M

+30.2%

Short Term Debt

$24.37M

-58.6%

Return on Assets

-23.23%

N/A

Return on Invested Capital

-28.89%

N/A

Free Cash Flow

$3.10M

-59.4%

Operating Cash Flow

$9.79M

-8.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRIXNurix Therapeutics, Inc.
$14.67-0.61%
KODKodiak Sciences Inc.
$33.66-9.03%
SEPNSepterna, Inc.
$23.30-2.39%
EYPTEyePoint Pharmaceuticals, Inc.
$11.85-5.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.52+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
INTCIntel
$41.19-0.04%
ONDSOndas
$8.15-0.07%

Questions About TNDM

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.